Medtronic Invests in Pi-Cardia to Advance Innovation for Complex TAVR
Medtronic announced a strategic investment in Pi-Cardia to strengthen its structural heart portfolio for complex transcatheter aortic valve replacement (TAVR) patients. Pi-Cardia’s ShortCut™ leaflet modification technology is the first FDA-cleared approach for valve-in-valve TAVR, with clinical studies showing successful leaflet splitting in all pivotal trial patients and a favorable safety profile.